By Stephen Nakrosis
Onconetix on Thursday said it named its interim Chief Financial Officer, Karina Fedasz, as interim Chief Executive Officer, effective immediately.
Also on Thursday, the biotechnology company said James Sapirstein resigned as executive chairman and as a member of the board.
Fedasz has helped companies raise capital, model and forecast business, manage cash flow and conduct mergers and acquisitions for more than two decades, Onconetix said. She has been interim CFO of Onconetix since June 2024. Before that, she worked with various clients, including a not-for-profit and an early-stage artificial intelligence and data-driven health and wellness tracker.
Prior to that, Fedasz was head of business development for Evofem Biosciences, and also served in various positions of increasing responsibility, including CFO, at IDW Media Holdings, Onconetix said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 03, 2025 18:34 ET (22:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。